Education
About Us
Working with TipRanks
Follow Us
Cormedix Inc. (CRMD)
:CRMD
CRMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.61 - $17.43
Previous CloseN/A
Volume1.29M
Average Volume (3M)2.26M
Market Cap
$868.59M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)51.8
Beta1.79
Next Earnings
Aug 07, 2025EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.30
Shares Outstanding74,429,170
10 Day Avg. Volume2,263,762
30 Day Avg. Volume2,261,125
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$17.38Price Target Upside50.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceCorMedix raised its Q2 net sales guidance to $35–40M, meaningfully improving analyst's near-term confidence in the durability of the launch and positions CRMD as a more visible and executable commercial growth story.
Large Dialysis Organization RolloutThe updated guidance follows a significantly broader-than-expected implementation of DefenCath with its Large Dialysis Organization partner, now set to begin rollout and targeting a 6,000-patient annualized run rate.
Bears Say
Inventory VolatilityVolume is expected to ramp gradually which should support more stable revenue recognition and reduce risk of inventory drawdown volatility.
Reimbursement RiskThe biggest risk to the company's story is the TDAPA reimbursement starting in July 2026.
Cormedix News
CRMD FAQ
What was Cormedix Inc.’s price range in the past 12 months?
Cormedix Inc. lowest stock price was $3.61 and its highest was $17.43 in the past 12 months.
What is Cormedix Inc.’s market cap?
Cormedix Inc.’s market cap is $868.59M.
When is Cormedix Inc.’s upcoming earnings report date?
Cormedix Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 6 days.
How were Cormedix Inc.’s earnings last quarter?
Cormedix Inc. released its earnings results on May 06, 2025. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.04.
Is Cormedix Inc. overvalued?
According to Wall Street analysts Cormedix Inc.’s price is currently Undervalued.
Does Cormedix Inc. pay dividends?
Cormedix Inc. does not currently pay dividends.
What is Cormedix Inc.’s EPS estimate?
Cormedix Inc.’s EPS estimate is 0.19.
How many shares outstanding does Cormedix Inc. have?
Cormedix Inc. has 74,429,170 shares outstanding.
What happened to Cormedix Inc.’s price movement after its last earnings report?
Cormedix Inc. reported an EPS of $0.3 in its last earnings report, beating expectations of $0.26. Following the earnings report the stock price went up 23.588%.
Which hedge fund is a major shareholder of Cormedix Inc.?
Currently, no hedge funds are holding shares in CRMD
Cormedix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.38 (50.61% Upside)
$17.38 (50.61% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 310.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
154.80%
12-Months-Change
Fundamentals
Return on Equity
19.87%
Trailing 12-Months
Asset Growth
119.90%
Trailing 12-Months
Company Description
Cormedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CRMD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for CorMedix presented a generally positive outlook with strong first-quarter sales, profitability, and optimistic revenue guidance for the first half of 2025. However, there were concerns regarding a predicted moderate revenue decline in Q2 and increased operating expenses. The initiation of a Phase 3 clinical study and an increase in cash reserves contribute to a positive sentiment.Read More>CRMD Stock 12 Month Forecast
Average Price Target
$17.38
▲(50.61%Upside)
Technical Analysis
Akebia Therapeutics
―
Kura Oncology
―
Urogen Pharma
―
Bicycle Therapeutics
―
Opthea Limited Sponsored ADR
―
Ownership Overview
2.02% Insiders
8.25% Mutual Funds
0.66% Other Institutional Investors
79.46% Public Companies and Individual Investors